Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
In a revolutionary first, Cancer Research UK-funded scientists will test whether the Zika virus can destroy brain tumor cells, potentially leading to new treatments for one of the hardest to treat cancers.
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the Food and Drug Administration as an investigational new drug for an early-stage clinical trial in the deadly brain cancer glioblastoma multiforme.
The University of Alabama at Birmingham and two partner institutions have received a European patent for their novel approach to fighting cancer, an approach that is led by the UAB spinoff biopharmaceutical company Incysus Ltd.
University of North Carolina Lineberger Comprehensive Cancer Center researchers and collaborators have mapped genetic changes that help drive an aggressive tumor as it develops in the brain – helping to lay the foundation for targeted treatment of the disease.
After her brain cancer became resistant to chemotherapy and then to targeted treatments, 26-year-old Lisa Rosendahl's doctors gave her only a few months to live.
A vaccine targeting cytomegalovirus (CMV) antigen pp65, combined with high-dose chemotherapy (temozolomide), improved both progression-free survival and overall survival for a small group of glioblastoma (GBM) patients.
Investigators at The Saban Research Institute of Children's Hospital Los Angeles have found that the gene PID1 enhances killing of medulloblastoma and glioblastoma cells.
Novocure announced today results from the second cohort of its phase 2 pilot PANOVA trial studying Tumor Treating Fields (TTFields) in combination with nab-paclitaxel and gemcitabine for the treatment of advanced pancreatic cancer.
Novocure announced today results from its phase 2 pilot INNOVATE trial studying Tumor Treating Fields (TTFields) in combination with weekly paclitaxel for the treatment of recurrent ovarian cancer.
A massive new study involving blood samples from over 30,000 individuals has identified 13 new genetic risk factors for glioma, the most common type of malignant brain tumor in adults
City of Hope, a world-renowned independent research and cancer and diabetes treatment center, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research at the Walter E. Washington Convention Center in Washington, D.C., April 1 to 5.
Being diagnosed with a malignant brain tumor is devastating news for patients and their loved ones. Whereas some types of tumor respond well to treatment, others such as glioblastomas - the most common and aggressive brain tumors - are known to recur and progress within short times from the diagnosis.
Treating older patients who have malignant brain cancer with the chemotherapy drug temozolomide plus a short course of radiation therapy extends survival by two months compared to treating with radiation alone, show clinical trial results published today in the New England Journal of Medicine.
Five types of pediatric brain cancer were safely and effectively treated in mice by an antibody that causes immune cells to engulf and eat tumors without hurting healthy brain cells, according to a new study by researchers at the Stanford University School of Medicine.
Mount Sinai researchers have discovered that a rheumatoid arthritis drug can block a metabolic pathway that occurs in tumors with a common cancer-causing gene mutation, offering a new possible therapy for aggressive cancers with few therapeutic options, according to a study to be published in Cancer Discovery.
Spherical nucleic acids are structures that are made by taking a nanoparticle template and using chemistry to arrange short strands of DNA or RNA on the surface of those particles. The spherical core of the nanoparticle creates a spherical arrangement of DNA or RNA, similar to tiny little balls of nucleic acids.
Researchers at the University of Cincinnati College of Medicine have discovered a new potential strategy to personalize therapy for brain and blood cancers.
In a rigorous study of tumor tissue collected from 125 patients with aggressive brain cancers, researchers at Johns Hopkins say they have found no evidence of cytomegalovirus (CMV) infection and conclude that a link between the two diseases, as claimed by earlier reports, likely does not exist.
Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an often fatal form of brain cancer, according to researchers at The University of Texas MD Anderson Cancer Center.
An analysis of a patient's deadly brain tumor helped doctors at Smilow Cancer Hospital identify new emerging mutations and keep a 55-year old woman alive for more than five years, researchers report in the journal Genome Medicine.